Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Insmed Incorporated - Common Stock (NQ:INSM)

153.32 +8.02 (+5.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Insmed Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
Analyst Expectations For Insmed's Future ↗
 
Via Benzinga
News headline image
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Is Insmed Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Insmed Stock In The Last 5 Years ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 20, 2025 ↗
 
Via Benzinga
News headline image
Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
In The Holiday Shortened Easter Week, These Large-Cap Stock Were Top Performers (Apr 14-Apr 18): Are These In Your Portfolio? ↗
Top performers last week: ServiceTitan, Summit Therapeutics, YPF, Eli Lilly, MicroStrategy, America Movil, Ericsson, Insmed, Diamondback, Neurocrine Biosciences. 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Insmed Stock In The Last 5 Years ↗
 
Via Benzinga
News headline image
Friday's after hours session: top gainers and losers ↗
As the regular session of the US market concludes on Friday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
Peering Into Insmed's Recent Short Interest ↗
 
Via Benzinga
News headline image
Insmed Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Insmed Stock In The Last 5 Years ↗
 
Via Benzinga
News headline image
A technical analysis of INSMED INC (NASDAQ:INSM). ↗
INSMED INC (NASDAQ:INSM) Reveals Intriguing Technical Aspects. Indications Suggest NASDAQ:INSM Could Be on the Verge of a Breakout. Here's What You Need to Know. 
Via Chartmill
News headline image
$1000 Invested In Insmed 10 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Expert Outlook: Insmed Through The Eyes Of 13 Analysts ↗
 
Via Benzinga
News headline image
One Vanguard Index Fund to Buy That May Beat the S&P 500 by 100% in the Next Few Years, According to a Wall Street Analyst ↗
Via The Motley Fool
Topics Stocks
News headline image
Are Small-Cap Stocks A Buy After Russell 2000 Correction? ↗
Investors are questioning the value of small-cap stocks, as reflected by Russell 2000's 15% drop. Some top stocks saw even bigger declines. 
Via Benzinga
News headline image
How Is The Market Feeling About Insmed? ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Insmed Stock In The Last 10 Years ↗
 
Via Benzinga
News headline image
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
First Trust's New Small-Cap ETF Aims To Combine Growth With Income ↗
First Trust launches actively managed FTKI ETF, using buy-write strategy for steady income and small-cap exposure. Expense ratio is 0.85%. 
Via Benzinga
Topics ETFs
News headline image
Lung Disease-Focused Insmed 'Is An Attractive Midcap Biotech,' Analyst Says ↗
RBC Capital initiates Insmed with an Outperform rating, citing brensocatib's launch potential and Arikayce's growth. FDA decision on brensocatib due August 2025. 
Via Benzinga
News headline image
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
Goldman Sachs Sees High Merger Odds For This Large-Cap Biopharma In Trump 2.0 Era: Retail Has Been Alert ↗
Insmed specializes in treatments for rare and serious diseases and is currently advancing its lead asset, brensocatib, a potential first-in-class therapy for bronchiectasis. 
Via Stocktwits
Topics Government
News headline image
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet ↗
The Benzinga Stock Whisper Index looks at five stocks receiving increased attention from readers during the week and provides potential reason why. 
Via Benzinga
News headline image
1 Vanguard Index Fund to Buy to Beat the S&P 500 in 2025, According to a Wall Street Bank ↗
Via The Motley Fool
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.